A pocket guide on how to structure SARS-CoV-2 drugs and therapies
- Resource Type
- Authors
- Julian P. Vivian; Gabrielle M. Watson; Dene R. Littler; Benjamin S. Gully; Bruce J. MacLachlan
- Source
- Biochemical Society Transactions
- Subject
- Models, Molecular
viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Genome, Viral
Disease
Computational biology
Virus Replication
Antiviral Agents
Biochemistry
Virus
Structure-Activity Relationship
Drug Development
Structural Biology
Virology
Drug Discovery
Humans
Medicine
Review Articles
Viral Structural Proteins
SARS-CoV-2
business.industry
Drug discovery
COVID-19
Therapeutics & Molecular Medicine
respiratory tract diseases
COVID-19 Drug Treatment
Clinical trial
Drug development
Structural biology
Viral replication
Spike Glycoprotein, Coronavirus
Protein Structural Elements
business
- Language
- ISSN
- 1470-8752
0300-5127
The race to identify a successful treatment for COVID19 will be defined by fundamental research into the replication cycle of the SARS-CoV-2 virus. This has identified five distinct stages from which numerous vaccination and clinical trials have emerged alongside an innumerable number of drug discovery studies currently in development for disease intervention. Informing every step of the viral replication cycle has been an unprecedented ‘call-to-arms' by the global structural biology community. Of the 20 main SARS-CoV-2 proteins, 13 have been resolved structurally for SARS-CoV-2 with most having a related SARS-CoV and MERS-CoV structural homologue totalling some 300 structures currently available in public repositories. Herein, we review the contribution of structural studies to our understanding of the virus and their role in structure-based development of therapeutics.